

# WILL Training page—December 2021



## NICE IOL guideline and the WILL trial

The new 2021 Inducing Labour guidelines (ng207) were released on 4 November 2021: (<https://www.nice.org.uk/guidance/ng207/resources/inducing-labour-pdf-66143719773637>).

These guidelines emphasise the importance of the research question addressed by WILL, and the lack of evidence to support optimal timing of birth at term gestational age.

The WILL trial aims to evaluate, among pregnant women with chronic or gestational hypertension that develops by 37<sup>+6</sup> weeks, the clinical effectiveness and cost-consequences of two different timing of delivery strategies:

- Planned early term delivery at 38<sup>+0</sup> to 38<sup>+3</sup> weeks
- Expectant care at term until at least 40<sup>+0</sup> weeks

The guideline makes **7 key research recommendations**, two of which are addressed by WILL for women with chronic or gestational hypertension at term gestational age:



### RESEARCH RECOMMENDATIONS:

#1 “Prevention of prolonged pregnancy: At what gestational age should induction of labour be offered in the subgroups of women who may be more likely to experience adverse outcomes if pregnancy continues?”

#2: “Based on individual patient data meta-analysis, what is the optimal timing of induction of labour?”

There is also **NO specific mention of guidance for women with pregnancy hypertension** or specifically, women with chronic or gestational hypertension near term – the population of interest for the WILL trial.



There are **benefits to trial participation** that extend beyond the potential benefits of the intervention, including improved outcomes, compared with non-participants. Also, in WILL as in other trials in pregnancy, the management strategy is high-quality and peer-reviewed, and the outcomes closely-tracked. These are being adjudicated, will be analysed rigorously, and potential subgroups of women who may benefit more (or least) examined.

Thank you for your support of this important NIHR-funded trial!

**Feedback:** Please could you provide us with any feedback on the information in this training page regarding the NICE IOL guideline and WILL? Does it help you with talking to women and doctors about WILL?

We can chat about this information during our next teleconference too.

Please email any feedback to [wiltrial@bham.ac.uk](mailto:wiltrial@bham.ac.uk)

